142 related articles for article (PubMed ID: 24752453)
1. Recurrent arthritis by Candida glabrata, a diagnostic and therapeutic challenge.
Erami M; Afzali H; Heravi MM; Rezaei-Matehkolaei A; Najafzadeh MJ; Moazeni M; Dolatabadi S; Hosseinpour L
Mycopathologia; 2014 Jun; 177(5-6):291-8. PubMed ID: 24752453
[TBL] [Abstract][Full Text] [Related]
2. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
3. Candida glabrata endophthalmitis treated successfully with caspofungin.
Sarria JC; Bradley JC; Habash R; Mitchell KT; Kimbrough RC; Vidal AM
Clin Infect Dis; 2005 Mar; 40(5):e46-8. PubMed ID: 15714407
[TBL] [Abstract][Full Text] [Related]
4. Candida glabrata-Induced Refractory Infectious Arthritis: A Case Report and Literature Review.
Chen S; Chen Y; Zhou YQ; Liu N; Zhou R; Peng JH; Qian QR
Mycopathologia; 2019 Apr; 184(2):283-293. PubMed ID: 30903581
[TBL] [Abstract][Full Text] [Related]
5. Azole resistant Candida glabrata vulvovaginitis treated with boric acid.
Savini V; Catavitello C; Bianco A; Balbinot A; D'Antonio F; D'Antonio D
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):112. PubMed ID: 19619928
[No Abstract] [Full Text] [Related]
6. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
7. The Inhibitory Effect of Human Beta-defensin-3 on
Inthanachai T; Thammahong A; Edwards SW; Virakul S; Kiatsurayanon C; Chiewchengchol D
Immunol Invest; 2021 Jan; 50(1):80-91. PubMed ID: 32316784
[No Abstract] [Full Text] [Related]
8. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.
Panackal AA; Gribskov JL; Staab JF; Kirby KA; Rinaldi M; Marr KA
J Clin Microbiol; 2006 May; 44(5):1740-3. PubMed ID: 16672401
[TBL] [Abstract][Full Text] [Related]
9. Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance.
Agnelli C; Guinea J; Valerio M; Escribano P; Bouza E; Muñoz P
Rev Esp Quimioter; 2019 Aug; 32(4):395-397. PubMed ID: 31327188
[No Abstract] [Full Text] [Related]
10. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).
Safdar A; Chaturvedi V; Koll BS; Larone DH; Perlin DS; Armstrong D
Antimicrob Agents Chemother; 2002 Oct; 46(10):3268-72. PubMed ID: 12234857
[TBL] [Abstract][Full Text] [Related]
11. Candida glabrata species complex prevalence and antifungal susceptibility testing in a culture collection: First description of Candida nivariensis in Argentina.
Morales-López SE; Taverna CG; Bosco-Borgeat ME; Maldonado I; Vivot W; Szusz W; Garcia-Effron G; Córdoba SB
Mycopathologia; 2016 Dec; 181(11-12):871-878. PubMed ID: 27681573
[TBL] [Abstract][Full Text] [Related]
12. Candida glabrata spinal osteomyelitis.
Dailey NJ; Young EJ
Am J Med Sci; 2011 Jan; 341(1):78-82. PubMed ID: 21030857
[TBL] [Abstract][Full Text] [Related]
13. The role of antifungal susceptibility testing in the therapy of candidiasis.
Hospenthal DR; Murray CK; Rinaldi MG
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):153-60. PubMed ID: 15023422
[TBL] [Abstract][Full Text] [Related]
14. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
Mann PA; McNicholas PM; Chau AS; Patel R; Mendrick C; Ullmann AJ; Cornely OA; Patino H; Black TA
Antimicrob Agents Chemother; 2009 Dec; 53(12):5026-34. PubMed ID: 19786600
[TBL] [Abstract][Full Text] [Related]
15. Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil.
Pasqualotto AC; Zimerman RA; Alves SH; Aquino VR; Branco D; Wiltgen D; do Amaral A; Cechinel R; Colares SM; da Rocha IG; Severo LC; Sukiennik TC
Infect Control Hosp Epidemiol; 2008 Sep; 29(9):898-9. PubMed ID: 18785850
[No Abstract] [Full Text] [Related]
16. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Drago M; Scaltrito MM; Morace G;
Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
[TBL] [Abstract][Full Text] [Related]
17. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.
Danby CS; Boikov D; Rautemaa-Richardson R; Sobel JD
Antimicrob Agents Chemother; 2012 Mar; 56(3):1403-6. PubMed ID: 22232293
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.
Ben-Ami R; Olshtain-Pops K; Krieger M; Oren I; Bishara J; Dan M; Wiener-Well Y; Weinberger M; Zimhony O; Chowers M; Weber G; Potasman I; Chazan B; Kassis I; Shalit I; Block C; Keller N; Kontoyiannis DP; Giladi M;
Antimicrob Agents Chemother; 2012 May; 56(5):2518-23. PubMed ID: 22314534
[TBL] [Abstract][Full Text] [Related]
19. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
20. Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient.
Westbrook SD; Wiederhold NP; Vallor AC; Kotara S; Bernardo S; Lee SA; Kirkpatrick WR; Toro JJ; Freytes C; Patterson TF; Redding SW
Med Mycol; 2010 May; 48(3):557-60. PubMed ID: 20370365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
